data has been undertaken to investigate the association of infused CD34 cell dose with various clinical outcomes after HLA-identical transplantation. Separate assessments for unrelated vs related donors and the use of bone marrow or mobilized G-CSF stimulated peripheral blood mononuclear cells (G-PBMC) have been incorporated. The three primary findings are: (1) Higher CD34 dose results in better neutrophil and platelet recovery in all settings. (2) Higher CD34 doses (>8 Â 10 6 /kg) are associated with the development of more chronic graft-versus-host disease when using related G-PBMC. (3) Higher CD34 dose is correlated with improved survival after unrelated donor bone marrow transplantation. These data suggest that the CD34 content of a graft can have a significant impact on clinical outcome after allogeneic transplantation, but defining an optimal dose is dependent on both the type of donor and the stem cell source.
Introduction
After allogeneic stem cell transplantation, outcomes such as survival or graft-versus-host disease (GVHD) depend on many patient-specific factors, but are also influenced by the source of stem cells, the make-up of different cell populations within the graft, and the degree of HLA matching between the donor and the recipient. [1] [2] [3] In this report, the Fred Hutchinson Cancer Research Center's (FHCRC) experience with both matched related and matched unrelated donors, the use of bone marrow or G-CSF mobilized peripheral blood mononuclear cells (G-PBMC) grafts, and quantitative enumeration of CD34 + hematopoietic stem/progenitor cells in those grafts is correlated with various clinical outcomes. One of the relevant questions that can be addressed with our large database of patient transplants is whether outcomes such as engraftment, GVHD and survival are associated with the number of CD34 + cells infused into the recipient. Data on the association of cell dose with outcome after cord blood transplantation has been recently published, and will not be covered in this paper. [4] [5] [6] One of the first considerations in this type of analysis are other variables such as the type of donor, related vs unrelated, and the source of CD34 + cells, bone marrow vs G-PBMC. These factors have clearly been shown to have an influence on clinical outcomes, and thus an analysis of CD34 + cell dosage effects must take these variables into account. Similarly, different clinical end points such as engraftment, GVHD, or survival must also be analyzed separately, as there is no a priori reason that particular CD34
+ cell doses will yield identical results in these various clinical settings. Finally, statistical methods must be employed to insure that other patient parameters (eg age, type of disease) that can also affect these clinical outcomes are accounted for in these correlative studies.
Quantitative flow cytometry is the preferred method to determine the number of CD34 + cells in a bone marrow or G-PBMC graft. There are a variety of different techniques that are employed among clinical laboratories, including the ISHAGE, Milan and Norway 7-9 protocols. Each of these methods utilizes slightly different staining combinations and gating strategies that can result in somewhat different values. Thus, when reporting CD34 dose-response relationship, the actual technique used must be acknowledged as that may have an effect on the reported values. It is important to keep in mind that when a specific dose is referred to here in this paper, it may not be exactly the same dose that would be determined by another lab using a different procedure. At the FHCRC, we routinely use a three-color combination of CD34-PE/CD14-FITC/7-AAD staining. Samples are first gated on total nucleated cells, followed by exclusion of nonviable 7-AAD + cells, followed by exclusion of CD14 + high-side scatter populations (previous work has shown that no true CD34 + cells are also CD14 + ), followed by gating on the brightest expressing CD34 + cell population. 10 It is this type of flow cytometry analysis that has been used for the correlative studies reported in this paper.
The FHCRC has developed a fairly large database over the last few years in which CD34 dosage information in the grafts has been determined. With respect to the different patient subgroups, there are currently 171 related and 265 unrelated bone marrow donors, while there are 371 related and 75 unrelated G-PBMC donors. The median doses of CD34 + cells vary between the subgroups, for bone marrow donors, related vs unrelated, the medians are 3.0 Â 10 6 /kg (range 0.8-19) and 2.8 Â 
Engraftment
In terms of short-term neutrophil engraftment, there is a significant difference between G-PBMC and bone marrow even when comparing similar doses of CD34 cells, with G-PBMC generally showing 5-7 days faster recovery times. Within the related G-PBMC subgroup, days to recovery of absolute neutrophil counts (ANC) greater than 500/ml plotted against infused CD34 + cell dose does show an association, higher dose yielding shorter times to engraftment. However, whether this is a clinically significant effect is somewhat up for debate. There does not appear to be a strict dose-response relation, with at most a 1-2 day maximum difference in terms of ANC recovery between the lower and higher CD34 doses. This may partly be an artifact of clinical trial design. Nearly all FHCRC allogeneic protocols require a minimum cell dose of 4 x 10 6 CD34 + cells/ kg. Thus, there are relatively few patients below this level, which may be above the threshold value where more significant delays in ANC recovery would occur.
The story with respect to platelet engraftment is very similar. Again there is a statistically significant association with higher CD34 dose yielding faster recovery times, with G-PBMC showing 5-12 days faster engraftment than bone marrow. At lower CD34 doses with related G-PBMC (o6 Â 10 6 /kg actual patient body weight), 10% of the patients do not recover their platelet counts within 30 days after transplantation, whereas at higher dose ranges (410 Â 10 6 /kg), all patients recover their counts above 20 000 by day 20. A similar effect is seen with slightly different kinetics for related bone marrow, where in this case patients with the lowest doses (o2 Â 10 6 /kg) show a longer time for platelet engraftment and a much higher proportion of patients do not recover their platelet counts to 20 000 before day 30.
Chronic extensive GVHD
In the related bone marrow setting, CD34 dose does not appear to correlate with chronic extensive GVHD (cGVHD), and with unrelated G-PBMC, we do not have enough data and long-term follow-up to make any definitive conclusions. With unrelated bone marrow transplantation there is a suggestion that higher CD34 doses do lead to increases in cGVHD, although this has not reached statistical significance. Our best correlation of CD34 dose and cGVHD has been obtained with related G-PBMC. We have previously published that, comparing patients that receive CD34 doses greater than 8 Â 10 6 /kg vs all others, there is a significant increase in cGVHD from 40 to 50%. 11 We have further explored this association in the current database. Separating the range of CD34 dosages into 20% quintiles, the lower four quintiles show identical levels of cGVHD, while the 5th quintile (410 Â 10 6 /kg) again shows a significantly higher rate of cGVHD. The biological explanation for this finding is unclear, one possible hypothesis for increased cGVHD may have to do with better reconstitution of donor dendritic cells from the larger number of CD34 + cells within the graft. 12 
Overall survival
Within the FHCRC data there appears to be no relationship between CD34 doses and overall survival in the case of related bone marrow or related G-PBMC. For related bone marrow, this finding is different from what has been published from other institutions. 3 However, in the case of unrelated G-PBMC there is a suggestion for CD34 dose affecting survival outcomes. Separating the dose of CD34 into quintiles, the two lowest quintiles (o7 Â 10 6 /kg) show the worst outcomes with survival at 1 year of 30-40%. The third and the fourth quintiles (7-10 Â 10 6 /kg) do better, with 1-year survival at 60-70%. The fifth quintile (410 Â 10 6 /kg) starts out similar to the third and fourth, but then tends to drop off with time so that at 1-year survival was only 40%. This sort of effect may indicate that, in the unrelated G-PBMC setting, an optimum CD34 dose may lie somewhere in the middle. Lower CD34 + cell dose is not optimal, and the highest CD34 doses are also not good, but this may be for a different reason such as increased GVHD (see above). Additional data, further follow-up, and more detailed analyses will be required to better explore this finding.
The most significant association of CD34 dose with survival was observed with the unrelated bone marrow transplants. Again splitting the CD34 dose into quintiles, a clear doseresponse relation was observed, with the lowest quintile having 40% survival at 2 years, next quintile at 50%, and the other quintiles at 60-70%. A more extensive multivariate analysis of this data adjusting for patient age and disease risk indicated that Figure 1 Probability of survival as a function of infused CD34 cell dose/kg for patients receiving an unrelated donor bone marrow transplant. Patients were divided into two groups based on above and below the median CD34 content of 2.7 Â 10 6 cells/kg. The two groups were comparable in terms of other clinical parameters. The data indicate a significantly improved survival for those patients who received higher doses of CD34 cells.
Figure 2
Differences in the median infused cell dose/kg between bone marrow and G-PBMC grafts. Samples were stained for the CD markers indicated on the X-axis, and analyzed using flow cytometry by methods similar to those described for the determination of CD34 as described in the text. The results indicate a three-fold difference in CD34 content, while T cells show a 10-fold difference, and CD14+ monocytes are 30-fold greater in G-PBMC. Similar 10-30-fold differences are seen with the other B-cell, NK and TNK fractions.
Importance of CD34 cell dose on stem cell transplantation S Heimfeld the most significant predictor for overall mortality was the dose of CD34 + cells. This is shown graphically in Figure 1 , where the unrelated bone marrow patients have been split into two groups, above and below the median CD34 dose of 2.7 Â 10 6 / kg. The improvement in overall survival seems to be driven by a reduction in nonrelapse mortality, that is, no difference in the relapse rates was seen between the patients getting the lower vs higher CD34 doses. There was a suggestion of an association with grades 3 and 4 acute GVHD, again with higher doses giving a lower effect. There was no evidence for any effect on chronic GVHD. In this analysis we also looked at a variety of other cell populations: CD14 monocytes, T-cell subset, B-cells, and NK-cells, but these other cell types did not change or improve the model to any significant extent. The best and only cell population that significantly predicted for improved survival was the dose of CD34 + cells. 13 
Conclusion
A prospective randomized trial has shown that there is a survival advantage for matched related allogeneic transplant recipients who received G-PBMC vs those who received bone marrow as a source of stem cells. 14 The biological basis for this advantage is not entirely clear. As noted above, G-PBMC have on average three-fold more CD34 + cells than bone marrow. However, this is unlikely to be the whole explanation for the improved survival, in almost every other lineage such as T-cell subsets, monocytes, B-cell, and NK cells, the differences are even larger (10-30-fold; see Figure 2 ). The association of these other cell populations with clinical outcomes is just beginning to be investigated. In a preliminary analysis for correlation with overall survival, higher doses of NK cells and particularly the TNK type cells seem to be the best predictors for improved survival after matched related allogeneic G-PBMC transplantation. In addition, there can also be qualitative as well as these quantitative differences. G-CSF mobilization and apheresis collection does result in significant changes in gene expression within the CD34 compartment when compared with bone marrow. 15 Other changes also occur in dendritic cell subsets after G-CSF mobilization. 16 In conclusion, we have examined the dose-response relationship of CD34 + cells in related and unrelated donor bone marrow or G-PBMC in terms of clinical outcomes such as engraftment, chronic GVHD and overall survival. In all cases, we can see that higher CD34 + cell doses lead to better recovery of neutrophils and platelets, although the clinical significance of that improved recovery is debatable. With related bone marrow there is no association of CD34 + dose with chronic GVHD or overall survival, but with unrelated bone marrow, higher CD34 dose does results in improved survival. In the related G-PBMC setting, no significant association is seen with overall survival with our present data; however, higher CD34 + doses (410 Â 10 6 /kg) are associated with more chronic GVHD. With unrelated G-PBMC, there is a suggestion that higher CD34 dose is associated with better survival, but more data and more long-term follow-up are necessary before a definite conclusion can be made. Finally, we are continuing to examine the association of other cell populations with clinical outcomes in each of these different clinical settings.
